Sugi Predict

Sugi Predict / Compounds / SCHEMBL149097

SCHEMBL149097

SCHEMBL149097

O=C(Cc1ccccc1)c1cc(Br)ccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSTA1 P08263 1/20 0.56
▸ HPGD P15428 3/20 0.55
▸ CES2 O00748 1/20 0.55
▸ GALR3 O60755 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ CASP1 P29466 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ MAPT P10636 3/20 0.54
▸ LMNA P02545 3/20 0.54
▸ GAA P10253 3/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ ALOX12 P18054 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ PTGES O14684 1/20 0.53
▸ AR P10275 1/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29586883 0.87 LMNA (0.67) GSTA1HPGDCES2MAPTLMNA
SCHEMBL7811476 0.84 PIK3CA (0.62) GSTA1HPGDCES2GALR3CYP1A2
SCHEMBL150523 0.84 LMNA (0.60) GSTA1HPGDCES2GALR3CYP1A2
SCHEMBL30494456 0.83 HPGD (0.47) GSTA1HPGDCES2GALR3CYP1A2
SCHEMBL11100 0.83 HPGD (0.47) GSTA1HPGDCES2GALR3CYP1A2
SCHEMBL9061935 0.83 ESR1 (0.59) HPGDMAPTLMNAGAANPC1
SCHEMBL5605436 0.81 PTGDR2 (0.47) HPGDMAPTLMNAGAANPC1
SCHEMBL152533 0.81 ALOX15 (0.51) GSTA1HPGDCES2GALR3CYP1A2
SCHEMBL11519 0.80 LMNA (0.55) HPGDALOX15MAPTLMNAGAA
SCHEMBL11069363 0.80 CSNK2A1 (0.58) HPGDALOX15MAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 — — US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 — — US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 — — US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 — — EP disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 — — US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 — — US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 — — US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
EP-0861242-B1 HETEROCYCLIC FUNGICIDES AVENTIS CROPSCIENCE UK LTD (GB) 2001-05-30 — — EP disclosed
US-6034121-A AGRICULTURE AGREVO UK LIMITED (GB) 2000-03-07 — — US disclosed
EP-0861242-A1 HETEROCYCLIC FUNGICIDES AgrEvo UK Limited (GB) 1998-09-02 — — EP disclosed
WO-1997013762-A1 HETEROCYCLIC FUNGICIDES AGREVO UK LIMITED (GB) 1997-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 GSTA1 2213/4885HPGD 2895/4885CES2 2414/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GSTA1 2335/4885HPGD 2910/4885CES2 3351/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GSTA1 2335/4885HPGD 2910/4885CES2 3351/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GSTA1 2335/4885HPGD 2910/4885CES2 3351/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GSTA1 2335/4885HPGD 2910/4885CES2 3351/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GSTA1 2335/4885HPGD 2910/4885CES2 3351/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A GSTA1 2272/4885HPGD 1641/4885CES2 3409/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GSTA1 2335/4885HPGD 2910/4885CES2 3351/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GSTA1 2335/4885HPGD 2910/4885CES2 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.